Nexvax2 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses Nexvax2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Nexvax2
- 3
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
ImmusanT, Inc. (3)
Studies
Open first, then newest update. How each study uses Nexvax2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)Status unknownPhase 2ImmusanT, Inc.NCT03644069Written as Nexvax2
- Safety and Tolerability of Nexvax2 in Subjects With Celiac DiseaseCompletedPhase 1ImmusanT, Inc.NCT02528799Written as Nexvax2
- Bioequivalence Study of Nexvax2 in Subjects With Celiac DiseaseCompletedPhase 1ImmusanT, Inc.NCT03543540Written as Nexvax2